Top 10 Biosimilar Services Companies in Europe - 2023
The biosimilar sector is gaining significant traction globally, presenting an opportunity for companies to thrive through innovation in commercial strategies, portfolio management, and accelerated research and development. With the evolution of regulatory landscapes, biosimilar prospects expand, and pricing dynamics become more agile, prompting companies to offer early discounts and rebates for specific channels and key accounts. A thriving biosimilar market promises to expand patient access to advanced yet affordable treatments and curb healthcare expenses. Achieving success in this environment hinges on balancing commercial approaches across diverse channels, necessitating a profound understanding of decision-making dynamics among physicians, patients, payers, and providers to tailor strategies accordingly.
According to market research, the global biosimilar market size was exhibited at $25.12 bn in 2022, and it is expected to surpass around $126.01 bn by 2032, at a CAGR of 17.6 percent. The global biosimilar market thrives due to its cost-effective approach to treating prevalent chronic diseases. Data analytics is pivotal in developing, evaluating, and obtaining FDA approval for biosimilars. These analyses, facilitated by cloud-based or AI-driven statistical tools, are essential for assessing biosimilars. Machine learning can help identify potential risk factors for immune reactions, enhancing biosimilar safety and cost-effectiveness.
This Life Sciences Review Europe edition brings the key developments in the biosimilars sector through thought leadership articles from Marc de Garidel, CEO and Interim Chairman, Abivax, and Piero Rijli, Corporate Director, Regulatory Activities and Market Access, MENARINI Group.
Marc de Garidel discusses the trends in the life science industry, focusing on the impact of technological advancements and the shift toward precision medicine. Piero Rijli navigates the implications of antimicrobial resistance (AMR), which poses a significant threat to the future of human health, and the need for raising awareness and conducting economic evaluations at the population level to account for externalities related to antibiotic use.
This edition features stories from companies that bring their solutions and services to this space.
In this edition featuring the Top Biosimilar Services Providers in Europe 2023, we hope you find the appropriate company suited to your business requirements.
Let us know your thoughts.
Nominate a Company
Usually, the qualified subscribers of our magazine nominate companies with whom they have collaborated and experienced exceptional results to be in this list. Did a company you recently worked with give you stellar results and ROI? Did it turn out to be one you would wholeheartedly recommend to peers? Or do you know of such an outstanding company through your network? Please fill in the details below and nominate them to be featured here.
Top Biosimilar Services Companies in Europe
